Raymond James initiated coverage of Cogent Biosciences (COGT) with a Strong Buy rating and $30 price target The firm thinks the company’s lead asset bezuclastinib possesses best-in-class potential in the “large and expanding” non-advanced systemic mastocytosis market. Key opinion leaders believe bezuclastinib possesses a differentiated profile, offering a meaningful efficacy and safety benefit, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences price target raised to $20 from $17 at Guggenheim
- Cogent Biosciences price target lowered to $21 from $22 at H.C. Wainwright
- Cogent Biosciences Reports Increased Losses Amidst Ongoing Development
- Promising Pipeline and Financial Stability Drive Buy Rating for Cogent Biosciences
- Cogent Biosciences reports Q2 net loss $73.529M vs $58.95M last year